BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW, Balmain A. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007;11:161-73. [PMID: 17292827 DOI: 10.1016/j.ccr.2006.11.025] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang F, Zhang H, Wang H, Qiu T, He B, Yang Q. Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations. Med Oncol 2022;39:180. [PMID: 36071247 DOI: 10.1007/s12032-022-01777-x] [Reference Citation Analysis]
2 Whately KM, Voronkova MA, Maskey A, Gandhi J, Loskutov J, Choi H, Yanardag S, Chen D, Wen S, Margaryan NV, Smolkin MB, Purazo ML, Hu G, Pugacheva EN. Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors. Oncogene 2021. [PMID: 34326467 DOI: 10.1038/s41388-021-01969-1] [Reference Citation Analysis]
3 Lee CL, Brock KD, Hasapis S, Zhang D, Sibley AB, Qin X, Gresham JS, Caraballo I, Luo L, Daniel AR, Hilton MJ, Owzar K, Kirsch DG. Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. Cancer Res 2021;81:3777-90. [PMID: 34035082 DOI: 10.1158/0008-5472.CAN-20-2823] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Liu X, Zhang Y, Wu S, Xu M, Shen Y, Yu M, Fan J, Wei S, Xu C, Huang L, Zhao H, Li X, Ye X. Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA. Biochem Pharmacol 2020;175:113933. [PMID: 32224138 DOI: 10.1016/j.bcp.2020.113933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
5 Liu N, Wang YA, Sun Y, Ecsedy J, Sun J, Li X, Wang P. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines. Respir Res 2019;20:230. [PMID: 31647033 DOI: 10.1186/s12931-019-1194-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
6 Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget 2016;7:50290-301. [PMID: 27385211 DOI: 10.18632/oncotarget.10366] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
7 Yang Q, Crispino JD, Wen QJ. Kinase signaling and targeted therapy for primary myelofibrosis. Exp Hematol 2017;48:32-8. [PMID: 28043820 DOI: 10.1016/j.exphem.2016.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017;102:719-727. [PMID: 28034990 DOI: 10.3324/haematol.2016.158394] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
9 Sasai K, Treekitkarnmongkol W, Kai K, Katayama H, Sen S. Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer. Front Oncol 2016;6:247. [PMID: 27933271 DOI: 10.3389/fonc.2016.00247] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
10 Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, Qi Z, Meng J, Zang R, Yang G. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget 2015;6:6670-83. [PMID: 25749384 DOI: 10.18632/oncotarget.3118] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
11 Nath S, Ghatak D, Das P, Roychoudhury S. Transcriptional control of mitosis: deregulation and cancer. Front Endocrinol (Lausanne). 2015;6:60. [PMID: 25999914 DOI: 10.3389/fendo.2015.00060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
12 Friis-Ottessen M, Burum-Auensen E, Schjølberg AR, Ekstrøm PO, Andersen SN, Clausen OP, De Angelis PM. TP53/p53 alterations and Aurora A expression in progressor and non-progressor colectomies from patients with longstanding ulcerative colitis. Int J Mol Med 2015;35:24-30. [PMID: 25333414 DOI: 10.3892/ijmm.2014.1974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Goldenson B, Crispino JD. The aurora kinases in cell cycle and leukemia. Oncogene 2015;34:537-45. [PMID: 24632603 DOI: 10.1038/onc.2014.14] [Cited by in Crossref: 159] [Cited by in F6Publishing: 164] [Article Influence: 19.9] [Reference Citation Analysis]
14 Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng J, Sun J, Yang G. Aurora-A: a potential DNA repair modulator. Tumour Biol 2014;35:2831-6. [PMID: 24277377 DOI: 10.1007/s13277-013-1393-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
15 Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50. [PMID: 24043741 DOI: 10.1200/JCO.2012.46.8793] [Cited by in Crossref: 148] [Cited by in F6Publishing: 153] [Article Influence: 16.4] [Reference Citation Analysis]
16 Joshi AJ, Gadhwal MK, Joshi UJ. A combined approach based on 3D pharmacophore and docking for identification of new aurora A kinase inhibitors. Med Chem Res 2014;23:1414-36. [DOI: 10.1007/s00044-013-0747-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
17 Lee SY, Lee GR, Woo DH, Park NH, Cha HJ, Moon YH, Han IS. Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells. Cell Cycle 2013;12:67-75. [PMID: 23255113 DOI: 10.4161/cc.22962] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
18 Albers J, Rajski M, Schönenberger D, Harlander S, Schraml P, von Teichman A, Georgiev S, Wild PJ, Moch H, Krek W, Frew IJ. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 2013;5:949-64. [PMID: 23606570 DOI: 10.1002/emmm.201202231] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
19 Hrabakova R, Kollareddy M, Tyleckova J, Halada P, Hajduch M, Gadher SJ, Kovarova H. Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy. J Proteome Res 2013;12:455-69. [PMID: 23151231 DOI: 10.1021/pr300819m] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
20 Hsueh KW, Fu SL, Chang CB, Chang YL, Lin CH. A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochim Biophys Acta 2013;1834:508-15. [PMID: 23201157 DOI: 10.1016/j.bbapap.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
21 Johnson EO, Chang KH, Ghosh S, Venkatesh C, Giger K, Low PS, Shah K. LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci 2012;125:1204-16. [PMID: 22492986 DOI: 10.1242/jcs.092304] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
22 Chiang CM. p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability. Cell Cycle 2012;11:3719-20. [PMID: 22982999 DOI: 10.4161/cc.22113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Wu CC, Yang TY, Yu CT, Phan L, Ivan C, Sood AK, Hsu SL, Lee MH. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle 2012;11:3433-42. [PMID: 22894933 DOI: 10.4161/cc.21732] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
24 Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2013;70:661-687. [PMID: 22864622 DOI: 10.1007/s00018-012-1073-7] [Cited by in Crossref: 242] [Cited by in F6Publishing: 253] [Article Influence: 24.2] [Reference Citation Analysis]
25 How J, Yee K. ENMD-2076 for hematological malignancies. Expert Opinion on Investigational Drugs 2012;21:717-32. [DOI: 10.1517/13543784.2012.668882] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
26 Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, Schultz LR, Williams CJ, Mikkelsen T, Brown SL, Ecsedy JA, Poisson LM. Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle 2012;11:489-502. [PMID: 22274399 DOI: 10.4161/cc.11.3.18996] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
27 Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs 2012;21:383-93. [PMID: 22242557 DOI: 10.1517/13543784.2012.652303] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
28 Michal AM, So CH, Beeharry N, Shankar H, Mashayekhi R, Yen TJ, Benovic JL. G Protein-coupled receptor kinase 5 is localized to centrosomes and regulates cell cycle progression. J Biol Chem 2012;287:6928-40. [PMID: 22223642 DOI: 10.1074/jbc.M111.298034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
29 Warnock LJ, Raines SA, Milner J. Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53. Cancer Biol Ther 2011;12:1059-68. [PMID: 22157150 DOI: 10.4161/cbt.12.12.18141] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
30 Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K. PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci 2011;124:2711-22. [PMID: 21807936 DOI: 10.1242/jcs.084970] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
31 Jen KY, Song IY, Banta KL, Wu D, Mao JH, Balmain A. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood 2012;119:805-9. [PMID: 22117044 DOI: 10.1182/blood-2011-01-327619] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
32 Chowdhury A, Chowdhury S, Tsai MY. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma 2012;53:462-71. [PMID: 21879811 DOI: 10.3109/10428194.2011.619018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG, DelRosario R, Huang EJ, Balmain A. Hipk2 cooperates with p53 to suppress γ-ray radiation-induced mouse thymic lymphoma. Oncogene 2012;31:1176-80. [PMID: 21785465 DOI: 10.1038/onc.2011.306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
34 Sumi K, Tago K, Kasahara T, Funakoshi-Tago M. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett 2011;585:1884-90. [PMID: 21557940 DOI: 10.1016/j.febslet.2011.04.068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
35 Frum RA, Zhang Y. The RP-p53-Mdm2 pathway: a new link to genetic integrity? Cell Cycle 2010;9:4427. [PMID: 21135577 DOI: 10.4161/cc.9.22.13606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Murphy ME. p53, transcriptional, and drug sensitivity: fresh perspectives on an old activity. Cell Cycle 2010;9:4432. [PMID: 21188768 DOI: 10.4161/cc.9.22.13927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
37 Kovar H. AURKA inhibitors: right in time. Pediatr Blood Cancer 2010;55:3-4. [PMID: 20486161 DOI: 10.1002/pbc.22548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, Mueller I, Savory WJ, Williams DH, Eyers PA. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol 2010;5:563-76. [PMID: 20426425 DOI: 10.1021/cb100053q] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
39 den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010;116:1498-505. [PMID: 20519624 DOI: 10.1182/blood-2009-11-251074] [Cited by in Crossref: 152] [Cited by in F6Publishing: 145] [Article Influence: 12.7] [Reference Citation Analysis]
40 Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 2010;16:3171-81. [PMID: 20423983 DOI: 10.1158/1078-0432.CCR-09-3171] [Cited by in Crossref: 73] [Cited by in F6Publishing: 84] [Article Influence: 6.1] [Reference Citation Analysis]
41 Wang Y, Zhang W, Edelmann L, Kolodner RD, Kucherlapati R, Edelmann W. Cis lethal genetic interactions attenuate and alter p53 tumorigenesis. Proc Natl Acad Sci U S A 2010;107:5511-5. [PMID: 20212136 DOI: 10.1073/pnas.1001223107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
42 Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11:934-44. [PMID: 19724687 DOI: 10.1593/neo.09664] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
43 Bibby RA, Tang C, Faisal A, Drosopoulos K, Lubbe S, Houlston R, Bayliss R, Linardopoulos S. A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. J Biol Chem 2009;284:33177-84. [PMID: 19801554 DOI: 10.1074/jbc.M109.032722] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
44 Torchia EC, Chen Y, Sheng H, Katayama H, Fitzpatrick J, Brinkley WR, Caulin C, Sen S, Roop DR. A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors. Cancer Res 2009;69:7207-15. [PMID: 19738056 DOI: 10.1158/0008-5472.CAN-09-1059] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
45 Abou Alaiwi WA, Lo ST, Nauli SM. Primary cilia: highly sophisticated biological sensors. Sensors (Basel) 2009;9:7003-20. [PMID: 22423203 DOI: 10.3390/s90907003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
46 Boss DS, Beijnen JH, Schellens JH. Clinical Experience with Aurora Kinase Inhibitors: A Review. The Oncol 2009;14:780-93. [DOI: 10.1634/theoncologist.2009-0019] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
47 Quigley D, Balmain A. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet 2009;10:651-7. [PMID: 19636343 DOI: 10.1038/nrg2617] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
48 Mendiola M, Barriuso J, Mariño-Enríquez A, Redondo A, Domínguez-Cáceres A, Hernández-Cortés G, Pérez-Fernández E, Sánchez-Navarro I, Vara JA, Suárez A, Espinosa E, González-Barón M, Palacios J, Hardisson D. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol 2009;40:631-8. [PMID: 19157502 DOI: 10.1016/j.humpath.2008.10.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
49 Cowley DO, Rivera-Pérez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O'Quinn R, Salmon ED, Magnuson T, Van Dyke T. Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol 2009;29:1059-71. [PMID: 19075002 DOI: 10.1128/MCB.01062-08] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 5.9] [Reference Citation Analysis]
50 Tian Z, An N, Zhou B, Xiao P, Kohane IS, Wu E. Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells. Cancer Chemother Pharmacol 2009;63:1131-9. [PMID: 18836721 DOI: 10.1007/s00280-008-0832-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
51 Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72. [PMID: 18662747 DOI: 10.1016/j.bbcan.2008.07.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 209] [Article Influence: 4.8] [Reference Citation Analysis]
52 Plotnikova OV, Golemis EA, Pugacheva EN. Cell cycle-dependent ciliogenesis and cancer. Cancer Res 2008;68:2058-61. [PMID: 18381407 DOI: 10.1158/0008-5472.CAN-07-5838] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 8.9] [Reference Citation Analysis]
53 Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008;12:69-80. [PMID: 18076371 DOI: 10.1517/14728222.12.1.69] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
54 Chia W, Somers WG, Wang H. Drosophila neuroblast asymmetric divisions: cell cycle regulators, asymmetric protein localization, and tumorigenesis. J Cell Biol 2008;180:267-72. [PMID: 18209103 DOI: 10.1083/jcb.200708159] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 7.9] [Reference Citation Analysis]